The chitin-binding domain of human macrophage chitinase was expressed as a fusion protein with glutathione S-transferase in Escherichia coli and assayed for its binding activity. The puriˆed recombinant chitin-binding domain bound to chitin, but not to glucan, xylan, or mannan. The binding of the recombinant chitin-binding domain to chitin was inhibited by Nacetylglucosamine, di-N-acetylchitobiose, and hyaluronan, but not by N-acetylgalactosamine or chondroitin. Furthermore, a solid-phase binding assay showed that the recombinant domain interacts speciˆcally with hyaluronan and hybrid-type N-linked oligosaccharide chains on glycoproteins, and that the oligosaccharidebinding characteristics are similar to those of wheat germ agglutinin, a lectin that binds to chitin. The results suggest that human chitinase chitin-binding domain may be involved in tissue remodeling through binding to polysaccharides or extracellular matrix glycoproteins, and this recombinant protein can be used to elucidate biological functions of the enzyme.
Key words: chitinase; chitin-binding domain; hyaluronan; glycoprotein; extracellular matrix Chitin, a b-1,4-linked homopolymer of N-acetyl-Dglucosamine, has not yet been found in mammals, although it is one of the most abundant polysaccharides in nature. Nevertheless, chitinases have been identiˆed in a variety of organisms ranging from bacteria to humans. [1] [2] [3] [4] [5] Human chitinase, a chitotriosidase expressed by macrophages, is elevated in serum from patients with Gaucher disease and detected in atherosclerotic plaques. Its physiological function remains unknown, although a defensive function and involvement in tissue remodeling events in atherogenesis have been suggested for this enzyme. Human chitinase is composed of two discrete domains, the catalytic and chitin-binding domains. The catalytic domain is contained within the N-terminal 75z of the protein. The C-terminal chitin-binding domain of human chitinase has been characterized using recombinant proteins expressed in mammalian cells or Saccharomyces cerevisiae.
6) These recombinant chitin-binding domains bound speciˆcally to chitin beads and fungal cell wall chitin.
Chitinases, which are important in hydrolyzing chitinˆbrils during the molting cycle in insects, have been proposed to be targets for the design of novel speciˆc insecticides, as humans were not believed to have those enzymes. Since macrophage endocrine chitinase 1, 2) and gastrointestinal tract exocrine chitinase 4) have been identiˆed in humans and it is possible that other chitinases are present in human tissues, however, in vitro assay systems must be established to evaluate the potential human health risks of exposures to such insecticides. The chitinase inhibitor, allosamidin, isolated from Streptomyces sp., 7) has been shown to inhibit the activity of insect chitinases speciˆcally. 8) These data suggest that a functional recombinant human chitinase can be a tool to test whether chitinase inhibitors as an insecticide aŠect chitinase activity in humans. And the recombinant chitin-binding domain also can be used as an important tool to understand physiological functions of human chitinase and may be a useful probe for identifying natural ligands in human tissues.
In this study, we describe the binding activity of a recombinant human chitinase chitin-binding domain (HCBD) expressed in Escherichia coli and its inter-action with chitin, hyaluronan (hyaluronic acid), and oligosaccharide chains of glycoproteins. The advantage of a bacterial fusion protein system is that the recombinant products can be easily handled and prepared on a large scale for repeated binding experiments. In addition, we discuss the possible application of the recombinant HCBD to elucidate biological functions of human chitinase.
Materials and Methods
Construction of expression plasmid. To produce a glutathione S-transferase (GST)-HCBD fusion protein, an E. coli expression plasmid that encodes the C-terminal 72 amino acids of human macrophage chitinase was constructed. The DNA encoding HCBD was prepared by polymerase chain reaction (PCR) using human genomic DNA (Roche) as a template based on the published nucleotide sequence. 2, 6) The HCBD region of the human chitinase gene contains no intron sequence. Sense and antisense primers for this PCR were 5?-CCGGATCCCAGAGCTTGA-AGTTCCAAAACC and 5?-CCGAATTCTCAAT-TCCAGGTGCAGCATTTGC ( BamHI and EcoRI sites are underlined). The PCR product encoding amino acid residues 395-466 of the chitinase was digested with BamHI and EcoRI, and then cloned in the BamHI and EcoRI sites of pGEX-3X (Amersham), yielding pGEX-3X W HCBD. The recombinant pGEX-3X W HCBD was introduced into competent E. coli JM109 cells. The nucleotide sequence of the expression construct was analyzed by dideoxy nucleotide sequencing to ensure the lack of errors.
Expression and puriˆcation of fusion protein.
The GST-HCBD fusion protein or GST alone was expressed in E. coli and puriˆed as described previously.
9) The puriˆed fusion protein was dialyzed against 10 mM Tris-HCl, pH 7.5, and then analyzed by 10z SDS-PAGE and immunoblotting. 10, 11) Proteins in the gel were stained with Coomassie Brilliant Blue (CBB) or transferred to a nitrocellulose membrane. The membrane was then stained with horseradish peroxidase (HRP)-conjugated anti-GST antibody (Amersham) to detect GST fusion proteins. Positive bands were visualized using the enhanced chemiluminescence detection system (Amersham). The molecular mass of the puriˆed fusion protein was measured by matrix-assisted laser desorption ionization time-of-‰ight mass spectrometry.
A‹nity chromatography. The binding speciˆcity of HCBD was identiˆed by a‹nity chromatography on various insoluble polysaccharides. 9, 12) The puriˆed GST-HCBD fusion protein was dissolved in a loading buŠer containing 125 mM NaCl, 10 mM CaCl2, and 25 mM Tris-HCl, pH 7.5. The fusion protein solution (0.5 ml) was put on a 1-ml column of chitin beads (New England Biolabs), glucan, xylan, or mannan (all from Sigma) equilibrated with the loading buŠer, and then washed with 5 ml of the loading buŠer. In some cases, 100 mM competing carbohydrates ( N-acetylglucosamine, di-N-acetylchitobiose, and N-acetylgalactosamine) or 1 mg W ml glycosaminoglycans (hyaluronan and chondroitin) were added to the loading buŠer and samples. The column was eluted with the elution buŠer (125 mM NaCl, 10 mM CaCl 2 , 100 mM competing monosaccharides, 25 mM Tris-HCl, pH 7.5). Competing monosaccharides included in the elution buŠer were N-acetylglucosamine, glucose, xylose, or mannose for a column of chitin beads, glucan, xylan, or mannan, respectively. Fractions were collected, and samples were analyzed by 10z SDS-PAGE. Fusion proteins were detected by silver staining. As a control, the binding activity of GST alone was tested under the same conditions.
Solid-phase binding assay.
To analyze the oligosaccharide-binding activity of HCBD, a solid-phase binding assay was done using four glycoproteins having diŠerent types of N-linked oligosaccharide chains: Ovalbumin, transferrin, fetuin, and asialofetuin (all from Sigma). Ovalbumin has heterogeneous high mannose-type chains and also has heterogeneous hybrid-type chains. 13, 14) Transferrin 15) has two biantennary complex-type chains and two more N-linked chains; one is probably biantennary and the other is a triantennary-type chain. Fetuin 16) has three equal triantennary complextype chains and three equal O-linked chains. Asialofetuin is obtained by removing sialic acids from fetuin. Polystyrene wells coated with various glycoproteins were blocked with a solution of 1z bovine serum albumin (BSA) in Tris-buŠered saline (TBS) (150 mM NaCl, 10 mM Tris-HCl, pH 7.5) for 2 h at room temperature. The binding assay was done by the addition of 100 ml of the puriˆed GST-HCBD fusion protein or GST in TBS containing 0.05z (v W v) Tween 20, 1z BSA, and 10 mM CaCl2 to the wells. In some cases, 100 mM competing monosaccharides were added to the reaction mixtures. The wells were incubated for 2 h and then washed three times with TBS containing 0.05z (v W v) Tween 20 and 10 mM CaCl2. After HRP-conjugated anti-GST antibody was added, the wells were incubated for 2 h and washed. Finally, wells were incubated with o-phenylenediamine and H2O2, and the absorbance at 492 nm was measured using a microplate reader. As a control experiment, coated wells were incubated successively with wheat germ agglutinin (WGA) (Sigma), anti-WGA antibody (Sigma), and HRPconjugated anti-IgG antibody (Amersham) as described above. Each assay was done in triplicate.
To analyze hyaluronan binding activity of HCBD, a solid-phase binding assay was done using Protein. The puriˆed fusion protein was put through mass spectrometric analysis and analyzed in the positive ion mode. biotinylated hyaluronan. Wells of microplates were coated with GST-HCBD fusion protein or GST at a concentration of 100 mg W ml and blocked as described above. The binding assay was done by the addition of 100 ml of biotinylated hyaluronan 17) in TBS containing 0.05z (v W v) Tween 20, 1z BSA, and 10 mM CaCl2 to the wells. In some cases, 100 mM competing carbohydrates were added to the reaction mixtures. The wells were incubated and washed as described above. Finally, the absorbance at 492 nm was measured as described above except for the use of HRP-conjugated streptavidin (Amersham). Each assay was done in triplicate.
Results

Production of GST fusion protein containing the chitin-binding domain of human macrophage chitinase
The GST-HCBD fusion protein containing the C-terminal chitin-binding domain of human macrophage chitinase was puriˆed (Fig. 1 ) and used to test its binding activity. SDS-PAGE and immunoblot analysis showed that the two puriˆed fusion proteins had the molecular sizes of 34 kDa and 32 kDa, respectively, and were detectable with anti-GST antibody. Analysis of the puriˆed protein by matrixassisted laser desorption ionization time-of-‰ight mass spectrometry showed two peaks with molecular masses of 34145.1 Da, a value that corresponds to the Wells of microplates were coated with GST-HCBD fusion protein or GST as indicated. The binding of GST-HCBD to hyaluronan was investigated by solid-phase binding assay using biotinylated hyaluronan as described in Materials and Methods.
Competing carbohydrates were present in the reaction mixtures as indicated. The values are the means of three independent experiments. The highest binding was taken as 100z. GlcNAc, N-acetylglucosamine; (GlcNAc) 2 , di-N-acetylchitobiose; Glc, glucose; Gal, galactose; GalNAc, N-acetylgalactosamine.
expected mass of 34111.6 Da for the full-length GST-HCBD fusion protein consisting of 226 amino acids of GST and 72 amino acids of HCBD, and 31695.3 Da, a value that corresponds to the molecular mass of 31704.7 Da for the degradation product consisting of 205 amino acids of GST and 72 amino acids of HCBD (Fig. 2) . These results indicate that the protein band with higher molecular size corresponds to the full-length GST-HCBD fusion protein and the protein band with lower molecular size was generated by cleavage of GST-HCBD fusion protein at the N-terminal region of GST. The protein band that corresponds to a peak with molecular mass of 29412.6 Da was barely detectable with CBB and it is probably a contaminant from E. coli proteins because of no reactivity with anti-GST antibody ( Fig. 1-B) . HCBD contains no potential N-glycosylation site, suggesting that N-linked oligosaccharides in this region are not required for the chitin-binding activity.
Chitin-binding activity of GST-HCBD fusion protein
The binding activity of GST-HCBD fusion protein wasˆrst examined by a‹nity chromatography. GST-HCBD bound speciˆcally to chitin, but did not bind glucan, xylan, or mannan (Fig. 3-A) . GST, the other portion of the fusion protein, did not bind to chitin (Fig. 3-A, lane 5) , suggesting that the observed chitin-binding activity of the fusion protein was due to the portion corresponding to HCBD.
Binding of HCBD to hyaluronan
The binding of GST-HCBD to a chitin bead column was inhibited by the addition of N-acetylglucosamine, di-N-acetylchitobiose, or hyaluronan, but not by the other carbohydrates like N-acetylgalactosamine and chondroitin (Fig. 3-B) . Since hyaluronan and chondroitin are polysaccharides having GlcUAb1-3GlcNAcb1-4 and GlcUAb1-3GalNAcb1-4 repeats, respectively, the presence of GlcNAc residues is thought to be necessary to achieve speciˆc binding of HCBD.
The solid-phase binding assay showed that GST-HCBD fusion protein binds to hyaluronan, and the binding was inhibited by N-acetylglucosamine and di-N-acetylchitobiose, but not by the other monosaccharides such as glucose, galactose, and N-acetylgalactosamine (Fig. 4) . GST showed no binding activity to hyaluronan. These results indicate that HCBD speciˆcally binds to hyaluronan and recognizes the N-acetylglucosamine moiety in carbohydrates.
Oligosaccharide-binding speciˆcity of HCBD The solid-phase binding assay showed that the GST-HCBD fusion protein preferentially binds to ovalbumin, having high mannose-type and hybridtype N-linked oligosaccharide chains, and the binding was inhibited by N-acetylglucosamine, but not by the other monosaccharides such as glucose, galactose, N-acetylgalactosamine, mannose, and fucose ( Fig. 5-A) . The binding characteristics of GST-HCBD were similar to those of WGA, a lectin that reacts with N-acetylglucosamine, chitin, and sialic acids, and also with hybrid-type N-linked oligosaccharide chains, 10) although WGA also bound to fetuin, having sialic acids (Fig. 5-B) . The binding of GST-HCBD to glycoproteins tested was dependent on their concentration and the maximal binding was seen at a concentration of 10 mg W ml (Fig. 5-C) . Therefore, it is unlikely that the observed diŠerences in the bindings in this assay are simply due to the diŠerences in the carbohydrate contents of glycoproteins used to coat the wells. GST alone showed no binding activity to oligosaccharides on glycoproteins (Fig. 5-D) . These results suggest that HCBD speciˆcally recognizes GlcNAc residues in hybrid-type chains of N-linked oligosaccharides.
Discussion
The chitin-binding domain of human macrophage chitinase is thought to be critical for targeting the enzyme to its substrate such as chitin in the fungal cell wall in vivo. It was also previously speculated that the human chitinase may modulate the extracellular matrix in the vessel wall and thus aŠect the downstream tissue-remodeling events associated with atherogenesis. 6) Since it is expected that the natural ligand for the human chitinase is an insoluble polysaccharide and W or extracellular matrix molecules in human tissues, the abilities of the chitin-binding domain to interact with hyaluronan and oligosaccharides on glycoproteins may be involved in tissue remodeling or pathophysiological states. The GST-HCBD fusion protein can be a probe to search for the natural ligands in human tissues because of its strict binding speciˆcity. Because this recombinant protein is functional, the full-length human chitinase expressed in E. coli could be used to evaluate the potential human health risks of exposures to novel chitinase-inhibitor insecticides. Our studies revealed a potential novel approach to develop systems to assess the safety of certain insecticides by using the recombinant human chitinase.
The biological roles of the human chitinase are ill-deˆned but presumably the enzyme contributes to a speciˆc defense against invading chitin-containing microorganisms. It remains to be elucidated whether the human chitinase plays other roles independent of the catalytic activity of the enzyme. The chitin-binding domain of the chitinase could preferentially bind to hybrid-type chains of N-linked oligosaccharides on glycoproteins in vivo, but extracellular matrix glycoproteins having hybrid-type chains have yet to be identiˆed so far. Fibronectin contains 4-9z carbohydrate and the major N-linked oligosaccharides are biantennary complex-type chains. 18) Laminin contains 12-15z carbohydrate and most of the carbohydrate is present in complex-type N-linked oligosaccharides. [19] [20] [21] However, since the structural studies of extracellular matrix glycoprotein carbohydrates are still in progress and the carbohydrate structure varies with the tissue source of the molecule, it is possible that some extracellular matrix molecules contain hybrid-type chains. It is interesting to note that laminin has poly-N-acetyllactosamines attached to N-linked oligosaccharides. 21) Poly-Nacetyllactosamine is a polysaccharide having Nacetyllactosamine (Galb1-4GlcNAc) repeats and structurally similar to chitin and hyaluronan in regard to the presence of GlcNAc residues. Extracellular matrix glycoproteins having poly-N-acetyllactosamine chains, such as laminin could be a potential ligand for the chitin-binding domain of human macrophage chitinase. It is possible that the human chitinase contributes to the formation of speciˆc extracellular matrix structures, although the enzyme contains no RGD sequence recognized by integrins. The human macrophage chitinase chitin-binding domain may immobilize the enzyme molecule to the extracellular matrix network, and hyaluronan and speciˆc glycoproteins such as laminin could function as scaŠolds that present ligands to the domain. The chitin-binding domain might be also involved in the regulation of various biological events by interactions with cell-surface carbohydrates.
